Metabolism of inflammation limited by AMPK and pseudo-starvation

Subjects

Abstract

Metabolic changes in cells that participate in inflammation, such as activated macrophages and T-helper 17 cells, include a shift towards enhanced glucose uptake, glycolysis and increased activity of the pentose phosphate pathway. Opposing roles in these changes for hypoxia-inducible factor 1β and AMP-activated protein kinase have been proposed. By contrast, anti-inflammatory cells, such as M2 macrophages, regulatory T cells and quiescent memory T cells, have lower glycolytic rates and higher levels of oxidative metabolism. Some anti-inflammatory agents might act by inducing, through activation of AMP-activated protein kinase, a state akin to pseudo-starvation. Altered metabolism may thus participate in the signal-directed programs that promote or inhibit inflammation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Central metabolic pathways involved in the Warburg effect in tumour cells and inflammatory cells.
Figure 2: Metabolic changes in TLR4-activated M1 macrophages.
Figure 3: Metabolic regulation of M2 macrophages and TH17 cells.
Figure 4: Regulation of AMPK by drugs, including anti-inflammatory drugs, and the principal metabolic pathways it regulates.

References

  1. 1

    Warburg, O. Metabolism of tumours. Biochem. Z. 142, 317–333 (1923).

  2. 2

    Oren, P., Farnham, A. E., Milofsky, M. & Marnovsky, M. L. Metabolic patterns in three types of phagocytizing cells. J. Cell Biol. 17, 487–501 (1963).

  3. 3

    Bennett, W. E. & Cohn, Z. A. The isolation and selected properties of blood monocytes. J. Exp. Med. 123, 145–159 (1966).

  4. 4

    Arwadi, M. S. & Newsholme, E. A. Maximum activities of some enzymes of glycolysis, the CS cycle and ketone body and glutamine utilization pathways in lymphocytes of the rat. Biochem. J. 208, 743–748 (1982).

  5. 5

    Newsholme, P., Curi, R., Gordon, S. & Newsholme, E. A. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem. J. 239, 121–125 (1986).

  6. 6

    Krawczyk, C. et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115, 4742–4749 (2010). This paper describes for the first time how lipopolysaccharide induces aerobic glycolysis in dendritic cells.

  7. 7

    Rodriguez-Prados, J. C. et al. Substrate fate in activated macrophages: a comparison between innate, classic and alternative activation. J. Immunol. 185, 605–614 (2010).

  8. 8

    Shi, L. Z. et al. HIF-1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367–1379 (2011).

  9. 9

    Dang, E. V. et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 146, 772–784 (2012). References 8 and 9 provide a detailed insight into the role of HIF-1α in T H 17 cells for the promotion of glycolysis and induction of RORγt.

  10. 10

    van der Windt, G. J. W. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68–78 (2012). This paper describes the predominance of mitochondrial metabolism in memory T lymphocytes.

  11. 11

    Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871–882 (2011).

  12. 12

    Everts, B. et al. Commitment to glycolysis sustains survival of nitric oxide-producing inflammatory dendritic cells. Blood 120, 1422–1431 (2012).

  13. 13

    Garedew, A., Henderson, S. O. & Moncada, S. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic death. Cell Death Differ. 17, 1540–1550 (2010).

  14. 14

    West, A. P. et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472, 476–482 (2011). A key role for mitochondrial ROS activated by TLR4 in bactericidal activity is described.

  15. 15

    Sonoda, J. et al. Nuclear receptor ERRα and coactivator PGC-1β are effectors of IFN-γ-induced host defense. Genes Dev. 21, 1909–1920 (2007).

  16. 16

    Vats, D. et al. Oxidative metabolism and PGC-1β attenuates macrophage-mediated inflammation. Cell Metab. 4, 13–24 (2006).

  17. 17

    Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic co-activator PGC-1. Cell 98, 115–124 (2010).

  18. 18

    Schwer, B. & Verdin, E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 7, 104–112 (2008).

  19. 19

    Liu, T. F., Vachharajani, V. T., Yoza, B. K. & McCall, C. E. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 287, 25758–25769 (2012).

  20. 20

    Yeung, F. et al. Modulation of NF-κB-dependent transcription and cell survival by Sirt1 deacetylase. EMBO J. 23, 2369–2380 (2004).

  21. 21

    Kelly, T. J., Lerin, C., Haas, W., Gygi, S. P. & Puigserver, P. GCN5-mediated transcriptional control of the metabolic coactivator PGC-1β through lysine acetylation. J. Biol. Chem. 284, 19945–19952 (2009).

  22. 22

    Lin, J., Handschin, C. & Spiegelman, B. M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361–370 (2005).

  23. 23

    Liu, T. F. et al. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J. Biol. Chem. 286, 9856–9864 (2011).

  24. 24

    Haschemi, A. et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab. 15, 813–826 (2012). This paper describes the role of CARKL in M2 macrophage function.

  25. 25

    Nishi, T. et al. Spatial redox regulation of a critical cysteine residue in NF-κB in vivo. J. Biol. Chem. 277, 44548–44556 (2002).

  26. 26

    Newsholme, P. & Newsholme, E. A. Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem. J. 261, 211–218 (1989).

  27. 27

    Infantino, V. et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem. J. 438, 433–436 (2011).

  28. 28

    Hedesov, C. J. & Esmann, V. Respiration and glycolysis of normal human lymphocytes. Blood 28, 163–174 (1966).

  29. 29

    Frauwirth K. A. et al. The CD28 signalling pathway regulates glucose metabolism. Immunity 16, 769–777 (2002).

  30. 30

    Michalek, R. D. et al. Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186, 3299–3303 (2011). This paper gives the first detailed description of the metabolic features of effector and regulatory T cells.

  31. 31

    Huo, Y. et al. Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis. Biochem. J. 444, 141–151 (2012).

  32. 32

    Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex. Mol. Cell 39, 171–183 (2010).

  33. 33

    Powell, J. D. et al. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39–68 (2011).

  34. 34

    Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009).

  35. 35

    Battaglia, M. et al. Rapamycin selectively expands CD4+CD25+Foxp3+ regulatory T cells. Blood 105, 4743–4748 (2005).

  36. 36

    Degoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signalling by mTORC1 and mTORC2. Nature Immunol. 12, 295–303 (2011). This article highlights the role of mTOR in metabolic regulation in T H cells.

  37. 37

    Peyssonnaux, C. et al. Essential role of hypoxia inducible factor-1α in development of lipopolysaccharide-induced sepsis. J. Immunol. 178, 7516–7519 (2007).

  38. 38

    Nizet, V. & Johnson, R. S. Interdependence of hypoxic and innate immune responses. Nature Rev. Immunol. 9, 609–617 (2009).

  39. 39

    Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645–657 (2003). This paper describes the crucial function of HIF-1α in inflammation.

  40. 40

    Imtiyaz, H. Z. et al. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699–2714 (2010).

  41. 41

    Pearce, E. L. et al. Enhancing CD8 T cell memory by modulating fatty acid oxidation. Nature 460, 103–107 (2009). This article is the first report on the key role of fatty-acid oxidation in mitochondria in memory T cells.

  42. 42

    Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108–112 (2009).

  43. 43

    Hawley, S. A. et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003).

  44. 44

    Woods, A. et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004–2008 (2003).

  45. 45

    Shaw, R. J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329–3335 (2004).

  46. 46

    Alessi, D. R., Sakamoto, K. & Bayascas, J. R. Lkb1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137–163 (2006).

  47. 47

    Lizcano, J. M. et al. LKB1 is a master kinase that activates 13 protein kinases of the AMPK subfamily, including the MARK/PAR-1 kinases. EMBO J. 23, 833–843 (2004).

  48. 48

    Hawley, S. A. et al. 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J. Biol. Chem. 270, 27186–27191 (1995).

  49. 49

    Davies, S. P., Helps, N. R., Cohen, P. T. W. & Hardie, D. G. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2Cα and native bovine protein phosphatase-2AC. FEBS Lett. 377, 421–425 (1995).

  50. 50

    Oakhill, J. S. et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 332, 1433–1435 (2011).

  51. 51

    Woods, A. et al. Yeast SNF1 is functionally related to mammalian AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo. J. Biol. Chem. 269, 19509–19515 (1994).

  52. 52

    Wilson, W. A., Hawley, S. A. & Hardie, D. G. The mechanism of glucose repression/derepression in yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Curr. Biol. 6, 1426–1434 (1996).

  53. 53

    Gancedo, J. M. Carbon catabolite repression in yeast. Eur. J. Biochem. 206, 297–313 (1992).

  54. 54

    Haurie, V., Sagliocco, F. & Boucherie, H. Dissecting regulatory networks by means of two-dimensional gel electrophoresis: application to the study of the diauxic shift in the yeast Saccharomyces cerevisiae. Proteomics 4, 364–373 (2004).

  55. 55

    Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M. & Esumi, H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287, 562–567 (2001).

  56. 56

    Jones, R. G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283–293 (2005).

  57. 57

    Lin, J., Handschin, C. & Spiegelman, B. M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361–370 (2005).

  58. 58

    Jager, S., Handschin, C., St-Pierre, J. & Spiegelman, B. M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc. Natl Acad. Sci. USA 104, 12017–12022 (2007).

  59. 59

    Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577–590 (2003).

  60. 60

    Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214–226 (2008).

  61. 61

    Shackelford, D. B. et al. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106, 11137–11142 (2009).

  62. 62

    MacIver, N. J. et al. The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J. Immunol. 187, 4187–4198 (2011).

  63. 63

    Sanchez-Cespedes, M. et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659–3662 (2002).

  64. 64

    Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558–565 (1995).

  65. 65

    Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001).

  66. 66

    Lee, Y. S. et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55, 2256–2264 (2006).

  67. 67

    Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403–416 (2006).

  68. 68

    Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607–614 (2000).

  69. 69

    El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223–228 (2000).

  70. 70

    Goransson, O. et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 282, 32549–32560 (2007).

  71. 71

    Hawley, S. A. et al. Use of cells expressing γ-subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11, 554–565 (2010).

  72. 72

    Soranna, D. et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17, 813–822 (2012).

  73. 73

    Pilon, G., Dallaire, P. & Marette, A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J. Biol. Chem. 279, 20767–20774 (2004).

  74. 74

    Nath, N. et al. 5-Aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 175, 566–574 (2005). This is the first report to give a detailed account of the anti-inflammatory effects of the AMPK activator AICA riboside.

  75. 75

    Nath, N. et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182, 8005–8014 (2009).

  76. 76

    Bai, A. et al. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol. 80, 1708–1717 (2010).

  77. 77

    Bai, A. et al. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J. Pharmacol. Exp. Ther. 333, 717–725 (2010).

  78. 78

    Myerburg, M. M. et al. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 42, 676–684 (2010).

  79. 79

    Zhao, X. et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L497–L504 (2008).

  80. 80

    Labuzek, K., Liber, S., Gabryel, B. & Okopien, B. AICAR (5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside) increases the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures. Neurotoxicology 31, 134–146 (2010).

  81. 81

    Nath, N. et al. Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem. Biophys. Res. Comm. 386, 16–20 (2009).

  82. 82

    Sag, D., Carling, D., Stout, R. D. & Suttles, J. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181, 8633–8641 (2008).

  83. 83

    Salminen, A., Hyttinen, J. M. & Kaarniranta, K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 89, 667–676 (2011).

  84. 84

    Marsin, A. S., Bouzin, C., Bertrand, L. & Hue, L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible phosphofructo-2-kinase. J. Biol. Chem. 277, 30778–30783 (2002).

  85. 85

    Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918–922 (2012). This paper describes how salicylates might mediate their anti-inflammatory effects through AMPK activation.

  86. 86

    Higgs, G. A., Salmon, J. A., Henderson, B. & Vane, J. R. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity. Proc. Natl Acad. Sci. USA 84, 1417–1420 (1987).

  87. 87

    Yin, M. J., Yamamoto, Y. & Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396, 77–80 (1998).

  88. 88

    Beckers, A. et al. Methotrexate enhances the anti-anabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol. Cancer Ther. 5, 2211–2217 (2006).

  89. 89

    Racanelli, A. C., Rothbart, S. B., Heyer, C. L. & Moran, R. G. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 69, 5467–5474 (2009).

  90. 90

    Rolf, J., Zarrouk, M., Finlay, D. K., Foretz, M., Viollet, B., Cantrell, D. A. AMPKα1: a glucose sensor that controls CD8 T-cell memory. Eur. J. Immunol. (in the press).

  91. 91

    Greer, E. L. et al. An AMPK–FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr. Biol. 17, 1646–1656 (2007).

  92. 92

    Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342 (2006).

  93. 93

    Canto, C. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1056–1060 (2009).

  94. 94

    Rothwell, P. M. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602–1612 (2012).

  95. 95

    Soranna, D. et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17, 813–822 (2012).

  96. 96

    Horman, S. et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase α-subunits in heart via hierarchical phosphorylation of Ser485/491. J. Biol. Chem. 281, 5335–5340 (2006).

  97. 97

    Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med. 6, 1288–1295 (2002).

  98. 98

    Matsui, T. et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J. Nucl. Med. 50, 920–926 (2009).

Download references

Acknowledgements

Work in the D.G.H. laboratory is supported by the Wellcome Trust and Cancer Research UK. Work in the L.O.N. laboratory is supported by Science Foundation Ireland and the European Research Council.

Author information

Correspondence to Luke A. J. O'Neill.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Additional information

Reprints and permissions information is available at www.nature.com/reprints.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

O'Neill, L., Hardie, D. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493, 346–355 (2013). https://doi.org/10.1038/nature11862

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.